

SURVEY OF PATIENTS TREATED AT HAEMOPHILIA CENTRES IN THE UNITED KINGDOM

Annual Returns for 1984 of Materials Used to Treat Haemophilia A Patients, Carriers of Haemophilia A and von Willebrand's Disease PatientsCentre: 163 Director: DR C. FORBES

Total number of Haemophilia A patients treated in 1984*;

Total number of Carriers of Haemophilia A treated in 1984:

Total number of von Willebrand's disease patients treated in 1984:

63
 2
 6 - ? (only 4 m...)

Type of Material Used	Total Amount of Material Used during 1984*** (including amount used for patients with F.VIII antibodies)					
	For Haemophilia A Patients		For Carriers of Haem. A		For von Willebrand's Disease Patients	
	Total used at Hospital (in-patients + out-patients)	Total used for Home Treatment	Total used at Hospital (in-patients + out-patients)	Total used for Home Treatment	Total used at Hospital (in-patients + out-patients)	Total used for Home Treatment
Plasma			4 packs + 250ml			
Cryoprecipitate	29,700		6,000		85,400	
NHS Human Factor VIII Conc.	854,274 +*	1,352,130 +*				
Alpha Factor VIII (Profilate)						
Armour Factor VIII (Factorate)						
Cutters Factor VIII (Koate)						
Travenol Factor VIII (Hemofil)	5,500					
Immuno Factor VIII (Kryobulin)						
Speywood Factor VIII (Humanate)						
Other Human Factor VIII Conc.**						
Porcine Factor VIII Conc.						
Other Materials (please specify)**	see A(2)					

*Please supply details on the computer print-out. **Please give name of manufacturer and/or trade name of product.

***Please enter the factor VIII units of activity; if this information is not available, please enter the number of bottles etc. used and specify that the figure is for bottles.

NB. See form A(2).

SURVEY OF PATIENTS TREATED AT HAEMOPHILIA CENTRES IN
THE UNITED KINGDOM

Annual Returns for 1984 of materials used for the treatment of
Haemophilia A patients who have Factor VIII antibodies (inhibitors)

Centre: 163

Number of Haemophilia A Patients with Factor VIII Antibodies
treated in 1984:

Type of material used	Amount used during 1984*	
	At Hospital	For Home Therapy
	F.VIII/IX Units	F.VIII/IX Units
Cryoprecipitate		
NHS Factor VIII Concentrate	25,210	27,060
<u>Commercial</u> Human F.VIII Concentrates**		
Porcine Factor VIII		
NHS Factor IX Concentrate		
<u>Commercial</u> Factor IX Concentrate**		
FEIBA	51,000	18,000
AUTOPLEX		
Other Materials (please specify):		

Comment (if any):

*The above treatments have not been included
in form A(1).*

* Please enter the factor VIII/IX units of activity: if this information is not available, please enter the number of bottles etc. used.

**Please give name of manufacturer and/or trade name of product.

SURVEY OF PATIENTS TREATED AT HAEMOPHILIA CENTRES IN THE UNITED KINGDOM

Annual Returns for 1984 of Materials Used to Treat Haemophilia B (Christmas Disease) Patients and Carriers of Haemophilia BCentre: 163 Director: DR C. FORBESTotal number of Haemophilia B patients treated in 1984*: 19Total number of Carriers of Haemophilia B treated in 1984*: 01

Type of Material Used	Total Amount of Material Used During 1984*** (including amount used for patients with F.IX antibodies)			
	For Haemophilia B Patients		For Carriers of Haemophilia B	
	Total Used at Hospital (in-patients + out-patients)	Total Used for Home Treatment	Total Used at Hospital (in-patients + out-patients)	Total Used for Home Treatment
NHS Factor IX Concentrate	128,300	256,700		
Commercial Factor IX**				
Other Materials (please specify)**			4 Pates + 750 units Plasma Protein Soln	

* Please supply details on the computer print-out

** Please give name of manufacturer and/or trade name of product.

*** Please enter the factor IX units of activity; if this information is not available, please enter the number of bottles etc. used and specify that the figure is for bottles.

CENTRE 163
HAEM.A PATIENTS
NAME

DIAG/ YR SX DOB F.3 YR TRT HT INHB HEP PLS. CRY NHS F.VIII COMMERCIAL F.VIII F.IX OTHER MTRLS EXTRA
REG.NO R6 79 INB 84 PRES 84 84 /85 OXF ELS EDN ALP ARM CUT TRA IMM OXF EDN MTRLS INFO

38-84 St Geo

GRO-A

GRO-A

76 M /62 16 76 M /60 04 76 M /55 17 69 M /58 00 70 M /67 00 77 M /63 08 76 M /61 07 69 M /55 00 69 M /37 18 76 M /38 10 76 M /09 07 74 M /48 00 76 M /69 02 69 M /01 07 73 M /46 01 69 M /42 00 69 M /32 00 69 M /32 15 77 M /22 30 69 M /47 22 69 M /51 04 77 M /66 01 76 M / 76 M /18 07 76 M /45 11 76 M /51 09

✓

✓

✓

✓

✓

✓

✓

✓

FEIBA

DAVP

transfused - 84

inhibitor level

NO RECORD

[illegible]

GRO-A

NO RECORD SINCE 1976

GRO-A

[illegible]

.....

.....

.....

.....

1. The first step in the process of creating a new product is to identify a market need. This involves conducting market research to understand the preferences and behaviors of potential customers. Once a need is identified, the next step is to develop a concept that addresses this need. This concept should be unique, feasible, and profitable. The third step is to create a prototype of the product. This allows the company to test the concept and make necessary adjustments. The fourth step is to conduct a feasibility study to determine if the product can be manufactured at a cost that allows for a profit. The final step is to launch the product into the market and monitor its performance. This involves tracking sales, customer feedback, and market trends to ensure the product remains competitive and profitable.

.....

[illegible]

1. The first step in the process of creating a new product is to identify a market need. This involves conducting market research to understand the preferences and behaviors of potential customers. Once a need is identified, the next step is to develop a concept that addresses this need. This concept should be innovative and differentiated from existing products in the market.

FP.

-? mark,

***NO RECORD

NAME

HAEM-A PATIENTS

CENTRE 163

GRO-A

GRO-A

GRO-A

GRO-A

12-13-68
No record source, 79

GRO-A

GRO-A

[illegible]

[illegible]

* * * * *

DIAG/ YR SX DOB F-8 YR TRT HT INHB HEP PLS CRY NHS OXF
%AN DET 84 IN 84 PRES 84 84 /85
F-IX MATERIALS RECEIVED IN 1984
F.VIII COMMERCIAL F.VIII TRA IWM OXF EDN
OTHER (SPECIFY)
OTHER
EXTN INTRN OP

NO REC
NO REC

TRAVERE
ROL

CENTRE 163

HAEN.A PATIENTS

NAME

DIAG/ YR SX DOB F.8 YR TRT HT INHB HEP MATERIALS RECEIVED IN 1984 (SPECIFY) EXTRA
REG.NO RG %AN DET 84 PRES 84 PLS CRY NHS F.VIII COMMERCIAL F.VIII F.IX OTHER MTRLS INFO
OXF ELS EDN ALP ARM CUT TRA IMM OXF EDN

GRO-A

GRO-A

74	M		37						*									*		
69	M		58 00	71					*									*		
69	M		59 00		✓	✓			*			✓						*		
77	M		66 01						*									*		
76	M		57 22						*									*		
76	M		34 00						*									*		
69	M	GRO-A	55 00		✓	✓			*			✓						*		
69	M		50 00		✓	✓			*			✓						*		
69	M		46 01		✓				*		✓							*		
76	M		49 12						*									*		
76	M		20 00						*									*		
77	M		64 07						*									*		
77	M		62 01						*									*		
76	M		/						*									*		
75	M		22 00	77	✓	✓	✓		*			✓						*		
76	M		57 03		✓	✓			*			✓						*		
76	M		52		✓				*			✓						*		
75	M	GRO-A	56 20		✓				*			✓						*		
74	M		54 10						*									*		
74	M		48 01	74			✓		*									*		
76	M		54 01	77			✓		*									*		
76	M		52 06						*									*		
76	M	GRO-A	63 06						*									*		
76	M		59 05						*									*		
76	M	GRO-A	61 07						*									*		
76	M		/	03					*									*		

Deceased ✓

FEIBA *inhibitor 1-5 G/8th

CENTRE 163

HAEM-A PATIENTS

NAME

DIAG/ REG.NO	YR RG	SEX	DOB	F.8 79 ZAN	YR IHB DET	TRT IN	HT 84	INHB PRES	HEP 84 785	PLS	CRY	NHS OXF	MATERIALS RECEIVED IN 1984										(SPECIFY)		EXTRA INFO
													F.VIII ELS	COMMERCIAL EDN	F.VIII ALP	F.VIII ARM	F.VIII CUT	F.VIII TRA	F.VIII IMM	F.IX OXF	F.IX EDN	OTHER MTRL			

GRO-A

GRO-A

GRO-A

No record since '76

No record since '76

Lives Ennlan

Lives in New
Zealand

Lives Ennlan

Attends New

DDAVP

No RECORD

No RECORD

CENTRE 163
HAEM.A PATIENTS
NAME

GRO-A

DIAG/ REG.NO	YR RG	SX	DOB	F.8 YR	TRT IN 84	HT PRES 84	INHB 84 /85	HEP	PLS	CRY	NHS	F.VIII	COMMERCIAL	F.VIII	F.IX	OTHER	EXTRA					
										MATERIALS RECEIVED IN 1984 (SPECIFY)												
										OXF	ELS	EDN	ALP	ARM	CUT	TRA	IMM	OXF	EDN	MTRL	LS	INFO
GRO-A	75	M	/31 02 75				✓	*				*				*	*					
GRO-A	69	M	/20 00					*				*				*	*					
GRO-A	76	M	/66 15					*				*				*	*					
								*				*				*	*					

↓

DAVP

HAEM. B PATIENTS

NAME _____

[illegible]

GRO-A

GRO-A

GRO-A

GRO-A

77-84 Treated

+ HIT Manchester children

GRO-A

*
*NO RECORD

HAEM.B PATIENTS

NAME

GRO-A

[illegible][illegible]

GRO-A

CENTRE 163
HAEM.A CARRIERS

NAME

DIAG/ YR SX DOB F.8 YR TRT HT INHB HEP MATERIALS RECEIVED IN 1984 (SPECIFY)
REG.NO RG 79 IHB IN 84 PRES 84 PLS CRY NHS F.VIII COMMERCIAL F.VIII F.IX OTHER EXTRA
ZAN DET 84 84 /85 OXF ELS EDN ALP ARM CUT TRA IMM OXF EDN MTRLs INFO

GRO-A

GRO-A

GRO-A

78 F /54 50

83 F /51 13

76 F /37 40

84 10/27/82

*
*
*
*
*

*
*
*
*
*

*
*
*
*
*

*
*
*
*
*

*
*
*
*
*

CENTRE 163
HAEM.B CARRIERS

NAME

DIAG/ YR SX DOB F.8 YR TRT HT INHB HEP
REG.NO RG /9 IHB IN 84 PRES 84 PLS CRY
%AN DET 84 84 /85

MATERIALS RECEIVED IN 1984 (SPECIFY)
NHS F.VIII COMMERCIAL F.VIII F.IX OTHER EXTRA
OXF ELS EDN ALP ARM CUT TRA IMM OXF EDN MTRLS INFO

GRO-A

GRO-A

80 F /46 19
76 F GRO-A /40 25
77 F /46 10

✓ GRO-A

F

✓

*
*
*
*
*

*
*
*
*
*

*
*
*
*
*

*
*
*
*
*

*
*
*
*
*

F.P.P.

CENTRE 163

VON WILLIBRANDS PATIENTS

NAME

DIAG/ YR SX DOB F.8 YR TRT HT INHB HEP MATERIALS RECEIVED IN 1984 (SPECIFY)
 REG.NO RG /9 IHB IN 84 PRES 84 PLS CRY NHS F.VIII COMMERCIAL F.VIII F.IX OTHER EXTRA
 %AN DET 84 84 /85 OXF ELS EDN ALP ARM CUT TRA IMM OXF EDN MTRL INFO

GRO-A

GRO-A

GRO-A

GRO-A

77	F	/56	10					*									*			*
83	F	/53	44					*									*			*
80	M	/33	05		✓			*	✓								*			*
79	F	/65	62					*									*			*
83		/						*									*			*
76	M	/52	62		✓			*	✓								*			*
78	F	/64						*									*			*
78	F	/35						*									*			*
77	F	/17	26		✓			*	✓								*			*
81	M	/67	73					*									*			*
83		/						*									*			*
77	F	/52	27					*									*			*
76	F	/47						*									*			*
77	F	/33	52		✓			*	✓								*			*
83	F	/						*									*			*
84	M	?	10					*									*			*

CENTRE 163

MISCELLANEOUS

NAME

DIAG/ YR SX DOB F-8 YR TRT HT INHB HEP
REG.NO RG 79 INB IN 84 PRES 84 PLS CRY
%AN DET 84 84 /85

MATERIALS RECEIVED IN 1984 (SPECIFY)
NHS F.VIII COMMERCIAL F.VIII F.IX OTHER EXTRA
OKF ELS EDN ALP ARM CUT TRA INM OXF EDN MTRLS INFO

GRO-A

GRO-A

81 M /08 00
81 F /54 04

*
*
*

*
*
*

*
*
*

*
*
*

*
*
*

CENTRE 166

HAEM.A PATIENTS

NAME

DIAG/ YR SX DOB F-8 YR TRI HT INHB HEP MATERIALS RECEIVED IN 1984 (SPECIFY)
REG.NO RG %AN DET 84 IN 84 PRES 84 84 /85 PLS CRY NHS F.VIII COMMERCIAL F.VIII F.IX OTHER EXTRA
OXF ELS EDN ALP ARM CUT TRA IMM OXF EDN MTRLS INFO

GRO-A

GRO-A

69 M 1/51 04
82 M 1/24 03
69 M 1/41 00
69 M 1/59 00
77 M 1/68 11
81 M 1/59 30

✓
✓
✓
✓
✗
✓

★
★
★
★
★
★

✓

✓
★
★
★
★
★
★

★
★
★
★
★
★
★

★
★
★
★
★
★
★

★
★
★
★
★
★
★

NO HT (letter)

GRO-A

67 M 3/67 1
69 13/69 < 1%
70 1/6/69 < 1%
64 1/9/63 < 1%
70 1/10/68 < 1%

✓
✓
✓
✓
✓

✓
✓
✓
✓
✓

BBAP

CENTRE 166
HAEM.B PATIENTS

NAME

DIAG/ YR SX DOB F.8 YR TRT HT IMHB HEP
REG.NO RG 79 INB IN 84 PRES 84 PLS CRY NHS F.VIII
%AN DET 84 84 /85

MATERIALS RECEIVED IN 1984 (SPECIFY)
OXF ELS EDN ALP ARM CUT TRA IMM OXF EDN MTRLs EXTRA INFO

GRO-A

GRO-A 76 M GRO-A 63 05

! ! ! ! * ! ! ! ! * ! ! ! ! * ! ! ! ! * ! ! ! ! *